Shareholder Alert: Ademi LLP investigates whether Alimera Sciences, Inc. has obtained a Fair Price for its Public Shareholders

PRNewswire 24-Jun-2024 12:39 PM

MILWAUKEE, June 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Alimera (NASDAQ:ALIM) for possible breaches of fiduciary duty and other violations of law in its transaction with ANI Pharmaceuticals.

Click here to learn how to join the https://www.ademilaw.com/case/alimera-sciences-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

In the transaction, Alimera public shareholders will receive only $5.50 per share in cash at closing and one non-tradable contingent value right (CVR) representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027. The transaction agreement unreasonably limits competing transactions for Alimera by imposing a significant penalty if Alimera accepts a competing bid. Alimera insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Alimera's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Alimera common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/alimera-sciences-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                                                                    
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-alimera-sciences-inc-has-obtained-a-fair-price-for-its-public-shareholders-302180426.html

SOURCE Ademi LLP